Stratified analysis according to clinical stage revealed that elevated AKIP1 expression reduced OS in patients with stage I-IV (HR = 1.70, 95% CI: 1.28–2.25, P < .001), stage I-III (HR = 1.71, 95% CI: 1.52–1.93, P < .001), stage I-II (HR = 1.64, 95% CI: 1.15–2.35, P = .007), M1-M6 (HR = 2.07, 95% CI: 1.32–3.25, P = .001), A–B (HR = 4.02, 95% CI: 3.05–5.31, P < .001), and none reported (HR = 3.07, 95% CI: 1.32–7.12, P = .009) cancer. Here, AKIP1 is linked to cancer.